BellaSeno

Executive Summary

BellaSeno is a German regenerative medicine company that has developed a proprietary additive manufacturing platform to produce fully absorbable scaffolds for tissue regeneration. Unlike permanent implants, these scaffolds mimic the extracellular matrix, supporting natural tissue ingrowth while gradually resorbing in the body, eliminating the need for removal surgeries. The platform enables patient-specific design and on-demand manufacturing, targeting high-value applications such as breast reconstruction post-mastectomy, chest wall reconstruction, and bone defects. Founded in 2015 and headquartered in Leipzig, BellaSeno has positioned itself at the intersection of 3D printing and regenerative medicine, addressing the limitations of current biologics and synthetic implants. The company's technology addresses a significant unmet need in reconstructive surgery, where patients often require multiple procedures and face risks of implant rejection or long-term complications. The global market for regenerative medicine scaffolds is projected to grow at a double-digit CAGR, driven by aging populations and rising demand for minimally invasive solutions. BellaSeno's regulatory pathway is progressing, with preclinical data demonstrating safety and efficacy in animal models. The company is well-positioned to capitalize on this trend as it advances toward clinical validation. While still private and pre-revenue, BellaSeno's innovative platform and strong IP portfolio make it a promising player in the regenerative medtech space.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation for breast reconstruction scaffold60% success
• Q4 2026CE marking submission for bone defect scaffold50% success
• Q1 2027Series B financing round closure70% success